Africa: The Slow Motion Race for a TB Vaccine
[spotlight] If the world had forgotten the importance of vaccines, COVID-19 has served as a stark reminder. Less than a year after the emergence of SARS-CoV-2 (the virus that causes COVID-19), over a hundred vaccine candidates are under development and several large clinical trials are already under way, including some in South Africa. It is plausible that a safe and effective COVID-19 vaccine will be available within the next year or two, although only time and properly conducted trials will tell. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - October 19, 2020 Category: Infectious Diseases Source Type: news
COVID-19: Examining Theories for Africa ’ s Low Death Rates
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The post COVID-19: Examining Theories for Africa’s Low Death Rates appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - October 11, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Africa Headlines Health Source Type: news
Could BCG vaccine protect against COVID-19? UK recruitment begins
(University of Exeter) A largescale global trial designed to test the theory that the widely-used BCG vaccine could help protect against COVID-19 will soon recruit healthcare staff and care home workers in the UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 11, 2020 Category: International Medicine & Public Health Source Type: news
UK study tests if BCG tuberculosis vaccine protects against coronavirus
Bacillus Calmette-Guerin (BCG) vaccine, used to protect against tuberculosis, induces a broad innate immune-system response and has been shown to protect against infection or severe illness with other respiratory pathogens. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 11, 2020 Category: Pharmaceuticals Source Type: news
Dartmouth TB Vaccine Moves Forward After Successful Phase 2 Trial
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - September 29, 2020 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Press Release Research Tanzania tubercolosis Source Type: news
Successful Dartmouth TB Vaccine Moves Forward After Phase 2 Trial
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - September 29, 2020 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Press Release Research Tanzania tubercolosis Source Type: news
Successful Dartmouth TB vaccine moves forward after phase 2 trial
(The Geisel School of Medicine at Dartmouth) Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 29, 2020 Category: Infectious Diseases Source Type: news
Researchers uncover early results about an existing tuberculosis vaccine that has been hypothesized to help against the coronavirus
While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts. This has led many researchers to suspect that BCG vaccine, which immunizes against tuberculosis, might offer protection against COVID-19. (Source: World Pharma News)
Source: World Pharma News - September 21, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Vaccination insights
(University of California - Santa Barbara) While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts. This has led many researchers to suspect that BCG vaccine, which immunizes against tuberculosis, might offer protection against COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 21, 2020 Category: Infectious Diseases Source Type: news
BCG vaccine safe for elderly, can protect against respiratory infections: Study
However the study, published in the journal Cell, cautioned that it is unclear whether the vaccine can prevent COVID-19 in the older sections of the population. (Source: The Economic Times)
Source: The Economic Times - September 2, 2020 Category: Consumer Health News Source Type: news
Elderly people protected against respiratory infections by BCG vaccine
(Radboud University Medical Center) The BCG vaccine has a broad, stimulating effect on the immune system. This gives it an effective preventive action against various infections - possibly also against COVID-19. New studies are investigating that. BCG is frequently given to children, but a double-blind randomized clinical study, a collaboration between Radboud university medical center and the National and Kapodistrian University of Athens shows that elderly people also benefit from it. The results are published in Cell. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news
TB vaccine shows encouraging results against coronavirus in phase-3 clinical trials
VPM1002, a tuberculosis vaccine, is showing encouraging results against the coronavirus infection in phase-III clinical trials being conducted in Germany. (Source: The Economic Times)
Source: The Economic Times - August 12, 2020 Category: Consumer Health News Source Type: news
Significantly improved COVID-19 outcomes in countries with higher TB vaccination coverage
(American Associates, Ben-Gurion University of the Negev) The researchers discovered that BCG regimes are associated with better COVID-19 outcomes, both in reducing infection rates and death rates per million, especially for ages 24 or younger who had received the vaccination in the last 15 years. There was no effect among older adults who had received the BCG vaccine. Many countries have stopped inoculating their entire population, but some still use BCG widely. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 12, 2020 Category: Infectious Diseases Source Type: news
BCG shots could slow down Covid-19 spread in first thirty days, says study
The paper published in Science Advances, a peer-reviewed medical journal brought out by the American Association for the Advancement of Science, said that countries with mandatory Bacillus Calmette-Gu érin (BCG) vaccination showed “slower infection and death rates” during the first 30 days of the Covid-19 outbreak in their country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 1, 2020 Category: Pharmaceuticals Source Type: news
Mandatory country-wide BCG vaccination found to correlate with slower growth rates of COVID-19 cases
(American Association for the Advancement of Science) Scientists have found that countries with mandatory Bacillus Calmette-Gu é rin (BCG) vaccination until at least the year 2000 tended to exhibit slower infection and death rates during the first 30 days of the outbreak (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 31, 2020 Category: Infectious Diseases Source Type: news
